SuhaylSamihDhib-JalbutMD

PubMed

• 215 citations
  Brain health: time matters in multiple sclerosis
  Gavin Giovannoni, Helmut Butzkueven, Suhayl Dhib-Jalbut, Jeremy Hobart, Gisela Kobelt
  Multiple Sclerosis and Related Disorders. 2016-09-01
• 53 citations
  Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
  Suhayl Dhib-Jalbut
  Pharmacology & Therapeutics. 2003-05-01
• 206 citations
  Interferon-β mechanisms of action in multiple sclerosis
  Suhayl Dhib-Jalbut, Steven Marks
  Neurology. 2010-01-05

Journal Articles

• Current use of biomarkers to guide MS therapies  
  Dhib-Jalbut SS, IJMSC, 10/1/2013
• From emerging agents to biomarkers: Integrating scientific advances into MS management  
  Dhib-Jalbut SS, Markowitz CE, Miller A, IJMSC, 1/1/2013
• Immune response during Interferon-beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse free in the START study  
  Dhib-Jalbut SS, Sumandeep S, Valenzuela RM, Ito K, Patel P, Rametta M, J Neuroimmunol, 1/1/2013
• Effect if interferon beta-1a on B71 and B72 B-cell expression and its impact on T-cell proliferation  
  Huang H, Ito K, Dangond F, Dhib-Jalbut SS, J Neuroimmunol, 1/1/2013
• Hematopietic progenitors expree myelin basic protein and ensheath axons in Shiverer brain  
  Goolsby J, Makar T, Dhib-Jalbut SS, Bever C, Pessac B, Trisler D, J Neuroimmunol, 1/1/2013
• Are Periventricular lesions specific for MS?  
  Casini G, Yurashevich M, Dash S, Dhib-Jalbut SS, Gerhardstein B, Balashov K, J Neurology & Neurophysiology, 1/1/2013
• HLA Dr and DQ alleles and Haplotypes associated with clinical response to Glatiramer Acetate in multiple Sclerosis  
  Dhib-Jalbut SS, Valenzuela RM, Ito K, Kaufman M, Picone MA, Buyske S, Multiple Sclerosis, 1/1/2013
• Comparison of IFN-B inducible gene expression in primary progressive and relapsing-remitting multiple sclerosis  
  Boppana S, Mindur JE, Balashov KE, Dhib-Jalbut SS, Ito K, J Neuroimmunol, 1/1/2013
• Use of Magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course  
  Cook SD, Dhib-Jalbut SS. et. Al, IJMSC, 1/1/2012
• The combined effect of nursing support and Adverse event mitigation on adherence to Interferon Beta-1b therapy in early multiple sclerosis  
  Dhib-Jalbut SS, Markowitz C, Patel P, Boateng F, Rametta M, for the START Study Group, IJMSC, 1/1/2012
• Immunologic aspects of multiple sclerosis  
  Boppana S, Huang H, Ito K, Dhib-Jalbut SS, Mount Sinai Journal of Medicine, 1/1/2011
• Biomarkers in Multiple Sclerosis  
  Graber J and Dhib-Jalbut SS, J Neurological Sciences, 1/1/2011
• Overlapping and distinct mechanisms of action of multiple sclerosis therapies  
  Graber J, McGraw CA, Kimbrough D, Dhib-Jalbut SS, Clinical Neurology and Neurosurgery, 9/1/2010
• Multiple Sclerosis Disease-Modifying Therapies: Mechanisms of Action and Practical Implications  
  Dhib-Jalbut SS, Neurology, 1/1/2010
• Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow cells as a vehicle  
  Makar T, Bever C, Singh I, Royal W, Sahu S, Sura T, Sultana S, Sura K, Patel N, Dhib-Jalbut SS, Trisler D, J Neuroimmunol, 1/1/2009
• Protective immunity in the nervous system  
  Graber J, Dhib-Jalbut SS, Pharmacology & Therapeutics, 1/1/2009
• Recognizing and treating suboptimally controlled multiple sclerosis:steps toward regaining command  
  Freedman M, Cohen B, Dhib-Jalbut SS, Jeffrey D, Reder A, Sandberg-Wolheim M, Weinstock-Guttman B, Current Medical Research & Opinion, 1/1/2009
• Stem cell-based delivery of IFN-B reduces relapses in Experimental Autoimmune Encephalomyelitis  
  Makar TK, Trisler D, Bever CT, Goolsby KT, Sura KT, Balasubramanian S, Sultana S, Patel N, Ford D, Singh IS, Gupta A, Valenzuela RM, Dhib-Jalbut SS, J Neuroimmunology, 1/1/2008
• Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlation with interferon dose and MRI response  
  Graber J, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut SS, J Neuroimmunol, 1/1/2007
• Ex-Vivo cellular IL-4/IFN-gamma correlates with clinical response to Glatiramer acetate in multiple sclerosis  
  Valenzuela R, Costello K, Johnson KP, Dhib-Jalbut SS, Multiple Sclerosis, 1/1/2007
• Pathogenesis of Myelin/Olgodendrocyte damage in Multiple Sclerosis  
  Dhib-Jalbut SS, Neurology, 1/1/2007
• Protective Autoimmunity  
  Dhib-Jalbut SS, Johns Hopkins Advanced Studies in Medicine, 1/1/2007
• Neuroprotection iin multiple sclerosis  
  Dhib-Jalbut SS, International Journal of MS care, 1/1/2006
• Immunomodulation and the basis for multiple sclerosis therapy  
  Dhib-Jalbut SS, International Journal of MS care, 1/1/2006
• Cellular immunological biomarkers of therapeutic response in multiple sclerosis  
  Dhib-Jalbut SS, International Journal of MS care, 1/1/2006
• Join now to see all

Lectures

• Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
  CMEducation Resources, LLC, San Jose, California - 4/20/2013
• Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
  CMEducation Resources, LLC, Dallas, Texas - 4/13/2013
• Minimizing Risks and Maximizing Efficacy for Management of Multiple Sclerosis 
  CMEducation Resources, LLC, Atlanta, Georgia - 4/6/2013